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Abstract 
Stable tethering of bioactive peptides like RGD to surfaces can be achieved via chemical 
bonding, biotin streptavidin interaction, or photo-crosslinking. More challenging is the 
immobilization of proteins, since methods applied to immobilize peptides are either not 
specific or versatile enough or might even compromise the protein’s bioactivity. To overcome 
this limitation, we have employed a scheme that by enzymatic (transglutaminase) reaction 
allows the site-directed and site-specific coupling of growth factors and other molecules to 
non-fouling poly(L-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG) coated surfaces under 
physiological conditions. By our modular and flexible design principle, we are able to 
functionalize these surfaces directly with peptides and growth factors or precisely position 
poly(ethylene glycol) (PEG)-like hydrogels for the presentation of growth factors as 
exemplified with vascular endothelial growth factor (VEGF).  
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Introduction  
 
Cells under physiological conditions are embedded within the extracellular matrix (ECM), a 
viscoelastic highly hydrated network that is mainly composed of glycosaminoglycans and 
fibrillar proteins. This ECM is not only responsible for structural integrity of tissues but also 
stores and presents complex spatiotemporal arrays of biochemical and biophysical signals1-4 
that regulate the dynamic behavior of cells or even whole tissues. Many growth factors are 
matrix bound and thus, only limited available to cells in quiescent tissues. Furthermore, 
matrix binding might restrict the diffusion of growth factors from the site of production, 
protect them from proteolytic degradation, and modulate their activity by coordination of 
integrin and tyrosine kinase receptor signaling. At this stage we are far from understanding 
the complex cell-matrix and cell-cell interactions involved in tissue formation, homeostasis, 
healing, and pathology. In order to study such events and to manipulate cellular behavior, test 
systems that in a predictable and biologically relevant manner present bioactive entities such 
as growth factors and cytokines are necessary.  
To mimic such complex in vivo environments, recent strategies take advantage of the virtual 
deconstruction of the ECM components into functional subunits, such as cell adhesion 
ligands, substrates for proteolytic enzymes, and immobilization of regulatory proteins2, 5-6. 
Protein and peptide components are synthesized by either chemical or by recombinant 
technologies, and incorporated by chemical, physical or biological means in a well-defined 
fashion either on surfaces7-10or in three-dimensional (3D) matrices2, 5, 11-12. Since in the 
naturally occurring situation multiple bioactive signals are presented in a tightly controlled 
tempero-spatial manner and in variable concentrations, such models should ideally be flexible 
and versatile enough to specifically, precisely and locally incorporate complex combinations 
and arrangements of motifs upon a passive background. Most important, mainly regarding 
incorporation of full proteins, the strategy used to stably immobilize bioligands should be 
mild enough to not compromise the protein's bioactivity.  
While strategies to spatially arrange bioligands in 3D are only beginning to be explored, 
modification and patterning strategies on surfaces are much further advanced and have been 
used to study cell-matrix interactions and to develop biomedical implants with improved 
healing and performance13. For example, surfaces modified with the well-known integrin 
peptide ligand RGD provided insight into substrate requirements for cell adhesion14-17 or cell 
migration18; into nanoscale spatial organization15, 19-20 and clustering of integrin receptors21-26. 
These studies have become possible due to the advances in micro- and nano-fabrication 
technologies8, 10, 24 that have allowed for the production of density- and space-controlled 
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immobilization of RGD binding peptides on non-fouling substrates like agarose, pluronics, 
and poly(ethylene glycol) (PEG), to prevent non-specific protein and cell adhesion. The 
arrangement of RGD peptides has for example been achieved by positioning of gold 
nanoparticles with immobilized cyclic RGD peptides on a bioinert PEG background. In an 
elegant system named molecular assembly patterning by lift off (MAPL)27, conventional 
photolithography is employed to create defined nano- and micropatterns of functionalized 
poly(L-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG) macromers on a non-fouling 
background. PLL-g-PEG-based copolymers were directly conjugated with cell adhesion 
ligands, such as RGD27-29, or with biotin which gives the possibility to immobilize different 
avidin-containing ligands at once30.  
In contrast to the relatively easy procedures to functionalize passive backgrounds with RGD 
peptides, the development of platforms that allow for the immobilization and arrangement of 
proteins, has been hindered by the many obstacles related to protein’s specific features. In 
order to not compromise the stability and activity of the proteins, sufficiently mild strategies 
that allow for site-specific and stable tethering of ligands which are compatible with the above 
mention technologies are needed. In recent years, some reports on successful immobilization 
of growth factors to surfaces by the use of different chemical, physical and biological means 
have been reported. Ichiose et al. described a direct chemical coupling of epithelial growth 
factor (EGF) to thiol modified glass-substrates using maleimide reactive groups previously 
conjugated to primary amine groups of the protein31. In another approach EGF was covalently 
immobilized to the hydroxyl-activated chains of coated poly(methyl methacrylate)-graft-
poly(ethylene oxide) (PMMA-g-PEO) on glass slides32. Soluble acryol-PEG-transforming 
growth factor-β1 (acryol-PEG-TGF-β1) has been proven to retain part of its bioactivity when 
added on glass slides modified with acryolyl-PEG-adhesive peptides33. Photo-immobilization 
strategies have been used to conjugate gradients of EGF and IGF-1 (insulin-like growth 
factor) modified to contain photoreactive groups onto polystyrene34. In an elegant strategy the 
group of Segura has taken advantage of the heparin-binding activity of vascular endothelial 
growth factor (VEGF) to “dock” and correctly orient the growth factor on heparin substrates. 
In a second step they use a photoreactive group to covalently “lock” the growth factor onto 
the surface35. Although chemical reactions have proven to be suitable for the tethering of 
growth factors to surfaces, the existing immobilization regimen lack versatility and general 
applicability since they are not compatible with a broad range of growth factors, and often 
might not result in a site-specific and properly oriented tethering of active proteins. Moreover, 
it is desirable to integrate such strategies in a micro-patterning context.  
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Enzymatic tethering of growth factors to substrates has been reported to be highly specific 
and due to mild reaction conditions are compatible with protein’s functionality36. For example 
transglutaminases, enzymes that rely on Ca2+ and introduce covalent cross-links between 
glutamine residues (glutamine donor) and lysine residues (glutamine acceptor), have been 
used to immobilize engineered enzymes or single-chain antibody fragments on amine-
terminated sepharose or on surfaces previously modified to contain casein in an active state37-
38. In previous work we have shown that factor XIIIa (FXIIIa), a transglutaminase isoenzyme, 
can be employed to cross-link star-shaped poly(ethylene glycol) (PEG) polymers that are 
functionalized with either a glutamine acceptor (Ac-FKGG)39 or a glutamine donor (H-
NQEQVSPL)40, here named; Lys substrate or TG substrates respectively, to form synthetic 
hydrogels41-42. The fidelity and specificity of the enzymatic reaction43-45, which takes place 
under physiological conditions is compatible with the protein functionality and could be 
applied simultaneously to tether growth factors and other ligands to the forming matrix41-42.  
In this study we describe a scheme that relies on the FXIIIa-enzymatic immobilization of 
biologically active ligands, including peptides and proteins on PLL-g-PEG coated surfaces. 
We show the specificity of the surface modification by Optical Waveguide Light Model 
Spectroscopy (OWLS) on PLL-g-PEG-based non-fouling surfaces. We demonstrate that this 
scheme is compatible with the well-established MAPL technology by creation of defined 
patterns of RGD and VEGF upon a passive PLL-g-PEG background. Initial results also 
indicate that based on consecutive enzymatic reactions, oriented build-up of surface-
immobilized hydrogel-like structures could be achieved in well-defined positions, giving the 
possibility to site-specifically deposit relatively large quantities of biologically active 
substances on a surface. 
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Materials and Methods 
All experiments (unless indicated) were performed in HEPES buffer, consisting of 10 mM 4-
(2-hydroxyethyl)-piperazine-1-ethane-sulfonic acid and 150 mM NaCl (Sigma Aldrich, 
Buchs, CH). The pH of the solution was adjusted to pH 7.4 using 6 M NaOH (Fluka, Buchs, 
CH). All aqueous solutions were prepared using ultrapure water filtered through MilliQ 
gradient A 10 filters (Millipore AG, CH).  
Poly(L-lysine)-graft-poly(ethylene glycol) (PLL-g-PEG) polymers 
Commercially available PLL20-g3.5-PEG2, PLL20-g3.5-PEG2-FITC4% (SurfaceSolutionS 
GmbH, Zurich, CH) and synthesized PLL20-g3.5-PEG2/3.4-TG were used in this study. The 
grafting ratio of the polymer g, determines the number of lysine monomer units per PEG side 
chain. This parameter, together with the molecular weight (mol wt) of the poly(L-lysine) 
backbone and the mol wt of the PEG side chains, were selected on the basis of prior work46. 
This PLL20-g3.5-PEG2 configuration has been shown to provide excellent performance in 
terms of resistance to protein adsorption when electrostatically adsorbed on negatively 
charged oxides.  
PLL20-g3.5-PEG2/3.4-TG was synthesized starting off from the protocol of VandeVondele47 as 
described in reference13. In brief, H-NQEQVSPLERCG-NH2 peptide (TG substrate) (mol wt 
1,358 g/mol, Neosystem, NeoMPS SA, Strasbourg, FRA) and heterofunctionalized PEG, with 
N-hydroxysuccinimide and vinylsulfone functional termini (NHS-PEG-VS) (mol wt 3,400 
g/mol, polydispersity 1.01, Nektar, Bradford, (UK)), were reacted for 5 min in a salt buffer 
solution containing 10 mM HEPES at pH 8.4. Poly(L-lysine) hydrobromide (PLL-HBr) with 
molecular weight of 20,000 g/mol (polydispersity 1.4, Sigma Aldrich, Buchs, CH) was 
dissolved in HEPES (10 mM, pH 8.4) and added to the reaction. After one hour N-
hydroxysuccinimidyl ester of methoxy terminated poly(ethylene glycol) (mPEG-NHS) (mol 
wt 2,000 g/mol, polydispersity 1.02, Sigma-Aldrich, Buchs, CH) was dissolved in HEPES (10 
mM, pH 8.4) and added to the final mixture that was stirred for 24 hours at room temperature. 
50 µl of β-mercaptoethanol (Fluka, Buchs, CH) was used for quenching and prior to freeze-
drying, the mixture was dialyzed against deionized water for 48 hours. Synthesized PLL-g-
PEG-TG resulted in a white powder and was kept frozen at -20°C before use.  
Grafting ratio g and fraction of peptide-functionalized PEG-chains were determined by 
Nuclear Magnetic Resonance Spectroscopy (1H-NMR) (Supporting information Figures S1, 
S3). Both the adsorption and the degree of resistance of the polymeric adlayers to serum 
adsorption were monitored in situ and quantitatively with Optical Waveguide Lightmode 
Spectroscopy (OWLS) (Supporting information Figure S2). The grafting ratio and the 
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adsorbed polymer mass allowed us to determine the surface densities of the immobilized 
peptide moieties29, 48.  
PEG and peptides 
Star-shaped 8-arm PEG, mol wt 40,000 g/mol, was purchased from Nektar (Huntsville, AL). 
Divinyl sulfone was purchased from Sigma-Aldrich (Buchs, CH). Substrate peptides for 
FXIIIa; Ac-FKGG-GPQGIWGQ-ERCG-NH2 (Lys substrate, mol wt 1,718 g/mol) and H-
NQEQVSPL-ERCG-NH2 (TG substrate, mol wt 1,358.5 g/mol), the two adhesion ligands Ac-
FKGG-RGDSP-NH2 (Lys-RGD, mol wt 1,018.3 g/mol), H-NQEQVSPL-RGDSPG-NH2 (TG- 
RGD, mol wt 1,539.6 g/mol) and the fluorescence ligand Ac-FKGGK(fluorescein)- NH2 
(Lys-FITC mol wt 966.2 g/mol) were obtained from NeoMPS (Strasbourg, F). TG-VEGF121 
(1.36 µg/µl dissolved in TBS, pH 7.4) was provided by P.D. Andreas Zisch (Clinic of 
Obstetrics, University Hospital Zurich, Zurich, CH).  
PEG vinylsulfone (PEG-VS) was produced and characterized as described elsewhere49. In a 
second step, PEG-VS were functionalized with Lys and TG substrates via Michel-type 
addition to give TG-PEG and Lys-PEG precursors. Functionalization and characterization of 
these precursors was performed as described elsewhere42. In brief, peptides were added to 
PEG-VS in a 1.2 fold molar excess over VS groups in 0.3 M triethanolamine (pH 8.0) at 37 
°C for 2 h, followed by dialysis (Snake Skin, MWCO 10k, PIERCE, Rockford, IL, USA) 
against ultrapure water for 4 days at 4 °C. 
Activation of FXIII by thrombin 
100 µl of FXIII (200 U/ml, Fibrogammin P1250 CSL Behring) was activated in presence of 
2.5 mM CaCl2 with 10 µl of thrombin (20 U/ml, Sigma-Aldrich, CH) for 30 min at 37 °C. 
Small aliquots (200 U/ml) of activated factor XIIIa were stored at -80 °C for further  
use41-42.   
Cell culture  
MC3T3-E1 mouse preosteoblastic cells from American Type Culture Collection (ATCC, 
Manassas, VA, USA) were grown in alpha-minimal essential medium (Gibco, Invitrogen, 
CH) supplemented with 10% (v/v) FBS at 37 °C and 5% CO2. Cells were trypsinized and 
passaged every 2 to 3 days. Cultures were never allowed to become confluent.  
Optical Waveguide Light Model Spectroscopy (OWLS) 
OWLS is an optical technique that allows for determining the adsorbed mass on a surface 
based on changes in the refractive index on the vicinity of the surface upon adsorption of 
molecules from solution. More details about this technique can be found elsewhere50. The 
instrument (OWLS 120) and the waveguides were obtained from MicroVacuum Ltd. 
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(Budapest, H). Waveguides were sputter-coated with 6 nm TiO2 at PSI (Villigen, CH).  
Shortly prior to use, waveguides were cleaned by ultrasonication for 10 min in 2-propanol and 
for 10 min in ultra-pure water, subsequently blown dried with filtered nitrogen and oxygen 
and plasma cleaned for 2 min (PDC-32 G. Harrick Plasma).  
For each experiment, the waveguide was mounted into a flow-through cell (15 µl volume) and 
HEPES was introduced. After stabilization of the buffer baseline, PLL-g-PEG-TG was 
injected and allowed to adsorb for at least 15 min before rinsing with HEPES. The protein 
resistance of the polymer was tested by injection of 3% bovine serum albumin (BSA) in 
HEPES. Subsequently, the surface was then exposed for 5 min to 25 mM CaCl2 in HEPES, 
rinsed with HEPES and the resistance of the polymer layer tested again with 3% BSA. 
Followed stabilization with the new buffer baseline (25 mM CaCl2 in HEPES 2), solutions for 
enzymatic surface modifications were injected and incubated for at least 30min. To determine 
the adsorbed mass for each modification we calculated the average mass difference before and 
after the injection of each solution. The adsorbed mass was calculated according to de 
Feijter’s formula, using a refractive index increment (dn/dc) of 0.139 cm3/g for PEG-based 
polymers and 0.182 cm3/g for proteins.  
Molecular Assembly Patterning by Lift off (MAPL) 
MAPL is a technique that allows for the production of micropatterns on a non-fouling surface 
via combination of conventional photolithography and assembly of functional PEG-graft 
polycationic copolymers on a negatively charged oxide-coated wafer. More details about this 
technique can be obtained elsewhere27. In brief, a photoresist layer was patterned (squares of 
60 x 60 µm) on a Nb2O5-coated MAPL wafer (ca. 10cm) by spin coating the surface with a 
photoresist, UV illumination through a mask and finally development. Afterwards, wafers 
were diced in 1 x 1 cm chips. Shortly before use, chips were cleaned by ultrasonication for 10 
min in ultra-pure water, dried with filtered nitrogen and oxygen plasma cleaned for 2 seconds. 
Subsequently either PLL-g-PEG-TG (0.5 mg/ml) or PLL-g-PEG-FITC (0.5 mg/ml) were 
immobilized on the unprotected areas of the substrate by spontaneous assembly from aqueous 
solution, followed by lift off of the photoresist in 1-methyl-2-pyrrollidone (NMP). In order to 
render the surface resistant to non-specific protein adsorption, bare metal oxide areas were 
backfilled with PLL-g-PEG.  
PLL-g-PEG, PLL-g-PEG-FITC and PLL-g-PEG-TG stocks (lyophilized white powder, kept 
frozen at -20 °C) were equilibrated at room temperature for 5 min prior to use and dissolved 
in HEPES 2 buffer to reach a final concentration of 0.5 mg/ml. Solutions were stored at -20 
°C and warmed up to room temperature before use. 
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Factor XIIIa-catalyzed coupling of bioligands onto the surface 
The TG-pendant domains patterned on the surface of the MAPL chips (squares of 60 x 60 
µm) were used to couple ligands containing a Lys substrate domain via factor XIII (FXIIIa) 
enzyme-catalyzed reaction to the surface. The MAPL wafers were incubated with either 100 
µl of i) Lys-FITC (50 µM), ii) Lys-RGD (50 µM) or iii) 8-arm Lys-PEG (200 µM) for 30 min 
at room temperature in presence of calcium (CaCl2, 25 mM) and FXIIIa (5 U/ml). Then the 
samples were rinsed 3 times for 5 min in HEPES and subsequently ultrasonicated for 2 min. i) 
Lys-FITC patterns were evaluated with the help of an epifluorescence microscope (Zeiss 
Microscope, Hamamatsu EM-CCD digital camera). As a negative control for the Lys-FITC 
pattern, a competitive assay was performed with soluble TG-RGD (200 µM) that competed 
with the TG residues on the surface. ii) Investigation of cell adhesion on the Lys-RGD 
patterns was performed in medium supplemented with 0.1% fetal bovine serum and 
antibiotics (100 U/ml penicillin G and 100 mg/ml streptomycin). MC3T3-E1 preosteoblastic 
cells were cultured at a density of 10,000 cells/cm2 for 4 hours and subsequently fixed and 
stained for f-actin as described below. As a negative control, a pattern of PLL-g-PEG-FITC 
on a PLL-g-PEG background was incubated with 100 µl of Lys-RGD (50 µM) in presence of 
FXIIIa (5 U/ml) and calcium (CaCl2, 25 mM) for 30 min at room temperature. iii) The 8-arm 
Lys-PEG tethered to the surface presenting still free, non-bound Lys domains was used in a 
second reaction step for FXIIIa-catalyzed immobilization of TG-VEGF121 (5.4 µg in 100 µl in 
HEPES). Binding of the growth factor to the surface was proved with VEGF specific first 
antibody (rabbit polyclonal VEGF (A-20) sc-152, Santa Cruz Biotechnology) followed by 
alexa fluor 555 goat anti-rabbit secondary antibody (A-21428, Invitrogen). As a negative 
control 8-arm Lys-PEG was not immobilized on the surface. 
Fixation and Staining Protocol 
MC3T3-E1 preosteoblastic cells were fixed and permeabilized in 4% paraformaldehyde 
containing 0.2% Triton X-100 in phosphate buffered saline (PBS) for 20 min at room 
temperature. Samples were washed for 5 min with 0.1 M glycine in PBS followed by a second 
washing step in PBS. For f-actin staining, samples were incubated (protected from light) with 
0.4 U/ml rhodamine-labeled phalloidin (Molecular Probes, Eugene, OR, USA) in PBS 1% 
BSA O.N. at 4 °C. Afterwards samples were washed 3 times for 5 min in PBS at room 
temperature and stored till evaluation.  
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Results and Discussion 
FXIIIa, involved in the fibrin clot formation, is an activated transglutaminase that catalyzes an 
acyl-transfer reaction between the R-carboxamide group of protein-bound glutaminyl (Gln, or 
Q in the single letter nomenclature) residues and the ε-amino group of lysyl (Lys, or K) 
residues, resulting in the formation of ε-(α-glutamyl) lysine isopeptide side-chain bridges44-45. 
In the initial step, FXIIIa interacts in a specific manner with the glutamine substrate which 
results in the formation of a thioester bond between the enzyme and the substrate and the 
release of ammonia. Afterwards, this enzyme-glutamine complex binds to the primary amine 
of the lysine containing substrate leading to an isopeptide bridge between the glutamine and 
the lysine, with the subsequent release of the enzyme43-44. In previous work we have shown 
that FXIIIa can be employed to crosslink star-shaped PEG polymers that are functionalized 
with either Lys or TG substrates to form synthetic hydrogels. Moreover, we have shown that 
the FXIIIa-catalyzed coupling scheme allows for the covalent incorporation of growth factors 
during the formation of these PEG hydrogels, without compromising the protein’s 
bioactivity41-42. Here, we aim to use this enzymatic reaction to site-specifically immobilize 
growth factors or other bioactive molecules on a surface.  
Design of the surface modification scheme 
To probe the specificity of the immobilization scheme we developed an approach that takes 
advantage of the above mentioned patterning technique; MAPL. In a first step, as depicted in 
Figure 1a, this MAPL technique27 is used to generate a pattern of PLL-g-PEG-TG (60x60 μm 
squares) in a non-fouling PLL-g-PEG background on a Nb2O5-coated surface. Next (Figure 
1b), the TG-pendant domains of the PLL-g-PEG-TG copolymer are employed for tethering of 
ligands designed to contain Lys-substrates, here 8-arm Lys-PEG, by FXIIIa to the surface. In 
a subsequent step, ligands that contain the counter reactive substrate for FXIIIa, TG substrate, 
are immobilized by the same reaction scheme to the immobilized non-reacted Lys substrates. 
Thus, by controlling the position of the TG residues on the surface and translating this pattern 
via the FXIIIa-enzymatic reaction into a bioactive pattern, it is possible to have control over 
the arrangement of the bioligands.  
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Figure 1.  Illustration of the scheme of factor XIIIa-catalyzed coupling of bioligands on a surface. (a) PLL-g-
PEG-TG is patterned on a non-fouling PLL-g-PEG background by Molecular Assembly Patterning by Lift-off 
(MAPL). (b) The TG pendant domains on the surface are used for enzymatic immobilization of bioligands that 
have been previously engineered to contain a factor XIIIa substrate sequence. Here, 8-arm Lys-PEG star-shaped 
macromers are bound to the surface. In a second step, vascular endothelial growth factor engineered to contain 
the TG sequence (TG-VEGF121) is linked to the immobilized non-reacted Lys Substrates.  
 
Synthesis and characterization of PLL-g-PEG-TG 
In order to position molecules on a surface, patterning strategies such as photolithographic, 
microfluidic, electrochemical techniques can be used. The PLL-g-PEG technology besides 
providing non-fouling properties to negative charged surfaces such as metals29, 46, 48, has been 
used together with MAPL to spatially arrange biologically active molecules like RGD on 
these surfaces and thus enable selective cell adhesion27. 
To allow the enzyme FXIIIa to locally and specifically interact with the protein-resistant 
surface coating, we functionalized the PLL-g-PEG copolymer with a pending TG substrate 
sequence (PLL-g-PEG-TG). PLL-g-PEG-TG was synthesized and characterized by 1H-NMR 
and OWLS (data included in Supporting information Figures S1, S2, S3). 1H-NMR rendered a 
grafting ratio of 4.4 and a content of peptide-functionalized PEG-chains versus total amount 
of PEG-chains of 25%. In situ measurement on a titanium-coated waveguide by OWLS 
rendered an adsorbed polymer mass of ca. 132 ± 5 ng/cm2 and a high degree of resistance of 
these polymeric adlayers to serum adsorption, shown by only ca. 1.8 ± 1.2 ng/cm2 protein 
adsorption. Both values were consistent with earlier publications29, 48. Based on the grafting 
ratio and the adsorbed polymer mass of our polymer, we calculated the surface density of the 
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immobilized TG-peptide moieties and the distance between them on a titanium-coated 
surface, and obtained 9.1 pmol/cm2 and 4.6 nm respectively, similar to values of peptide 
moieties reported by other groups27-29. 
Patterning of FITC- labelled Lys substrates 
Since the coating of titanium-coated surfaces with PLL-g-PEG-TG proved to be resistant to 
protein adsorption (Supporting information Figure S2), we next created patterns of 
functionalized PLL-g-PEG-TG copolymers in a non-fouling PLL-g-PEG background by 
MAPL. We wanted to test whether the TG domains on the surface of PLL-g-PEG were 
accessible for tethering of biomolecules by FXIIIa. Therefore, we designed a short peptide 
sequence consisting on the TG-counter reactive substrate for FXIIIa followed by a short linker 
and fluorescein; Lys-FITC, which allowed us to directly follow the coupling reaction to the 
free pending TG peptide on the surface. After the reaction of Lys-FITC (50 μM) in presence 
of FXIIIa and calcium ions, the surfaces were washed thoroughly and analyzed by 
epifluorescence microscopy. In initial experiments the corresponding pattern of 60 x 60 µm 
green squares (false colored), separated by 100 µm, could be visualized at a wavelength of 
470 nm on a dark background (Figure 2a). As negative control we performed a competitive 
assay using a large excess of soluble TG over bond TG substrates. The addition of TG-RGD 
(200 μM) in the Lys-FITC (50 μM) mixture resulted in a surface with an undetectable 
fluorescence pattern (Figure 2b). These results imply that the TG domains on the surface were 
still functional and accessible for FXIIIa and that binding of the Lys-FITC molecules to the 
surface was indeed mediated by FXIIIa activity. 
Enzymatic tethering of the integrin binding ligand RGD 
Next, we wanted to test whether this modification scheme could be used to tether biologically 
relevant molecules. Previous findings indicated that functionalized PLL-g-PEG-RGD on 
metal implant surfaces sustained the adhesion of cells and could be used for tissue 
engineering applications such as the development of biomedical implants with improved 
healing and performance in vivo13, 29. To prove the specific coupling of Lys-RGD to PLL-g-
PEG-TG coated surface via FXIIIa reaction, Nb2O5-coated surfaces were patterned with either 
PLL-g-PEG-TG or PLL-g-PEG-FITC on a cell- and protein-resistant background. After 
incubation with the Lys-RGD containing reaction mix, the non-bound ligands were carefully 
removed by rinsing. The presence and availability of the RGD peptide was assessed by 
allowing adhesion of MC3T3-E1 preosteoblastic cells for 4 hours under low serum (0.1%) 
cell culture conditions. As expected, cells exclusively attached to the areas were PLL-g-PEG-
TG was immobilized (Figure 2c) and neither to the immobilized PLL-g-PEG-FITC (Figure 
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2d) nor to the PLL-g-PEG background, as shown by epifluorescence microscope imaging. 
These results prove that the squares covered by PLL-g-PEG-TG translate into bio-adhesive 
patterns (RGD), and that the Lys-RGD ligands tethered to the surface are available to the 
cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Enzymatic immobilization of Lys modified substrates on a surface by MAPL and OWLS. (a) 60x60 
µm pattern of FITC-labeled Lys substrate; (b) same in the presence of soluble TG-RGD in the incubation 
mixture (competitive assay); (c) MC3T3 cells on the RGD-functionalized pattern, (d) cells on a pattern without 
the RGD functional group. Fluorescence intensity (in gray scale, original colored images) was measured with 
“ImageJ’s Plot Profile”. The scale bar corresponds to 100 µm. (e-g) In situ surface immobilization of different 
ligands on PLL-g-PEG-TG coated waveguides by OWLS (three independent experiments, (-) control, (+) 
positive sample, (*) significantly different, (NO*) no significantly different (statistical analysis performed “dunn 
test”),  n=3). 
 
Theoretical RGD ligand density 
In this study we did not evaluate the influence of the RGD ligand density on cell spreading or 
focal adhesion formation. However, we calculated the maximum theoretical Lys-RGD surface 
e f g 
dc 
a b
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peptide density and the distance between the moieties on both surfaces29, based on the 
polymer structure and the adsorbed PLL-g-PEG-TG mass on the surface (132 ng/cm2 on 
TiO2-coated surfaces (measured by OWLS), 170 ng/cm2 on Nb2O5-coated surfaces (from 
bibliography27). We obtained a density of 9.1 pmol/cm2 (9.2 ng/cm2) and a distance of 4.6 nm 
for TiO2-coated surfaces and a density of 11.7 pmol/cm2 (11.9 ng/cm2) and a distance of 4 nm 
for Nb2O5-coated surface (Supporting information Figure S3). Such values are in the range of 
reported values on PLL-g-PEG-RGD copolymer (3.36 pmol/cm2 and 8 nm) that have been 
proven to activate focal adhesion sites on titanium surfaces29. Moreover, integrin α5β3-
mediated fibroblast spreading has been reported to occur at a mean RGD peptide spacing of 
440 nm (corresponding to 0.001 pmol/cm2), while focal contact formation and extensive f-
actin stress fibers has been reported to require a mean spacing of ≤ 140 nm (corresponding to 
0.01 pmol/cm2)14. That such Nb2O5-coated wafers remain stable over more than ten days, and 
thus can be used to culture cells, has been shown in defined patterns of PLL-g-PEG-RGD and 
PLL-g-PEG51.  
In situ surface modification by OWLS  
Besides testing the specificity of FXIIIa surface modification by MAPL, we also wanted to 
determine the amount of ligands that can be coupled to our surfaces by FXIIIa enzymatic 
reaction. Thus, we monitored the adsorption of ligands on PLL-g-PEG-TG-coated 
waveguides (TiO2-coated) in situ by OWLS (Supporting information Figure S4 for a 
representative OWLS experiment; two immobilization steps). Prior to enzymatic modification 
of PLL-g-PEG-TG-coated surfaces, we tested the resistance of the coated-surfaces to BSA 
(3%) and to the effect of calcium ions (25mM) (data not shown). Experiments shown in 
Figure 2e-g correspond to three independent experiments and include the adsorption values 
(ng/cm2) of each molecule (n=3) with the corresponding standard deviation (SD). As 
mentioned before, FXIIIa first interacts in a specific manner with the TG domain, resulting in 
the formation of an enzyme-glutamine complex and the subsequent interaction of the complex 
with a Lys domain. At this stage the stability of this complex in absence of the Lys substrate 
is unclear. Based on previous work44 and our own reported observations42 the modification on 
the TG substrate due to the hydrolysis of one glutamine residues into a glutamic acid residue 
is occurring. This hydrolysis might not only affect the affinity of FXIIIa for the TG sequence 
but more importantly might induce the complete inactivation of the substrate. In a first set of 
experiments we tested the interaction of FXIIIa with the PLL-g-PEG-TG-coated surface. The 
increase in the mass adsorbed on the surface in response to FXIIIa application (5.1 ± 0.9 
ng/cm2) indicates the interaction between the enzyme and the TG substrate in absence of Lys 
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substrate. The specificity of this interaction could be demonstrated by the absence of adsorbed 
mass (0.9 ± 1.1 ng/cm2) upon addition of 8-arm TG-PEG (400 µM) to the reaction mixture 
(Figure 2e). In the next set of experiments, the binding of Lys-FITC was assessed in 
conditions that either did not contain or contained FXIIIa (Figure 2f). As expected, an 
increase in mass (5.7 ± 0.9 ng/cm2) consistent with the theoretical calculated mass (8.8 
ng/cm2. Supporting information Figure S3) was observed only when FXIIIa was present. 
However since Lys-FITC is a small molecule (966.2 g/mol), this increase was not 
significantly different from the one obtained for FXIIIa. Therefore, in the next set of 
experiments (Figure 2g) we modified the surface with the ca. 55 fold larger star-shaped 8-arm 
Lys-PEG (53,744 g/mol) under the same reaction conditions. A significant increase in mass 
(26.4 ± 3.3 ng/cm2) was detected only in presence of FXIIIa. This value corresponds to lower 
molar coverage than the one we would expect when considering the theoretically available 
number of TG domains on the surface. The reason for this low mass increase could be 
explained considering the size of the molecule. Our theoretical calculations assumed the best 
hypothetical conditions which are; excess of Lys substrate (ensured it in our experimental 
design), functionality of glutamine substrate on the surface (previously proved by MAPL), 
complete accessibility of the TG substrates, and 100% efficiency in the enzymatic reaction. 
Based on the polymer configuration and on previous work by other groups27, the probability 
that a fraction of TG ligands on the surface, is embedded within the dynamic PEG-brush 
during the 30 min incubation period is very low. The coupling efficiency of the enzyme based 
on previous work should be ca. 80-85%41-42. This later reasoning is supported by the in situ 
increase in mass measured for Lys-FITC, a small molecule which diameter we assumed to be 
< 4.6 nm (theoretical distance between TG moieties ca. 4.6 nm). In the case of 8-arm Lys-
PEG (ca. 20-30 nm in diameter), we believe that each molecule tethered to the surface blocks 
the access of ca. 10 TG moieties due to steric hindrance. Both this steric hindrance and the 
enzymatic efficiency, could explain the mass adsorption quantified by OWLS in the case of 8-
arm Lys-PEG (Supporting information Figure S3).   
Surface immobilization of vascular endothelial growth factor by MAPL and OWLS 
Once we proved that the TG domains immobilized on the surface can be used for the site-
specific enzymatic binding of ligands, we wanted to proceed by the building up of a second 
layer of macromers in a sequential fashion as depicted in Figure 1b. The stepwise coupling of 
layers would be useful for the flexible and modular design of surface properties, for example 
for immobilization of growth factors in well defined positions. To test the specific 
incorporation of our prototypic growth factor TG-VEGF121 (Figure 1b scheme) we prepared 
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two different MAPL substrates. In the first coupling step, PLL-g-PEG-TG patterns (60x60 
µm) were reacted in presence or in absence of star-shaped 8-arm Lys-PEG which should 
result in surfaces that did or did not contain free surface-exposed Lys substrates. If these 
substrates are accessible for FXIIIa they should in a next reaction step be available for the 
linkage of a further layer. Therefore, substrates decorated with free Lys domains when reacted 
in presence of TG-VEGF121 (5.4 µg) and FXIIIa should present the growth factor in an active 
and properly oriented fashion. The surface immobilization and distribution of TG-VEGF121 
was proved with a polyclonal rabbit anti-VEGF antibody followed by a goat anti-rabbit IgG 
labeled with alexa 555. As expected 60x60 µm squares (with some inhomogeneities)  
contrasted clearly with a dark background in the samples that contained the Lys-PEG layer, 
while an uniform background was observed for the negative sample and the non-fouling 
regions from the positive sample (Figures 3a-b). These results indicate a site-specific tethering 
of TG-VEGF121 on the regions where the corresponding substrate for FXIIIa (Lys-PEG) was 
previously immobilized. 
The build-up of the surface layers was then confirmed by OWLS. First the tethering of 8-arm 
Lys-PEG was followed (26.4 ± 3.3 ng/cm2). Afterwards the surface was exposed to FXIIIa 
and calcium, as expected; no significant mass increase was detected (0.06 ± 1.1 ng/cm2). On 
the contrary, a significant mass increase of 10.1 ± 3 ng/cm2 was measured when TG-VEGF121 
was added to the reaction mixture (Figure 3c).  
To discuss TG-VEGF121 immobilization values we first consider how Lys-PEG is presented 
on the surface. When considering that the 8-arm Lys-PEG molecule will present a cubical 
geometry with each arm directed towards one of the 8 vertex of the cube, the edge length 
would be in the range of 11.6 to 17.3 nm (arm size of Lys-Peg ca. 10 - 15 nm). Based on the 
surface area occupied by one Lys-PEG molecule (11.62 to 17.32) and assuming whole 
coverage of the surface, the total amount of Lys-PEG molecules that fit per cm2 will range 
from 3.3E11 (molecule diameter; 20 nm) to 7.4E11 (molecule diameter; 30 nm); which is 
comparable to the experimental number of Lys-PEG molecules (26.4 ± 3.3 ng/cm2, 2.9E11 
molecules). As already suggested we believe that only one out of 10 TG moieties is occupied 
by an 8-arm Lys-PEG molecule (total TG density: 9.1 pmol/cm2 (9.2 ng/cm2); 1/10 of total 
density and 80% efficiency on the surface represents 4.4E11 Lys-PEG molecules). Therefore, 
we believe that the surface is saturated with a monolayer of Lys-PEG molecules. At this stage 
we don’t know how many Lys motifs at the terminus of each PEG will be accessible by 
flexibility and molecular dynamics for further modifications by the FXIIIa enzymatic 
reaction. Calculations for TG-VEGF121 immobilization (as well as for TG-PEG) indicate that 
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ca. one dimeric growth factor interacts with one 8-arm Lys-PEG molecule (15.7 ± 2 ng/cm2 of 
TG-VEGF121 expected when 1 mol of 8-arm Lys-PEG interacts with 1 mol of TG-VEGF121; 
and 62.9 ± 7.9 ng/cm2 when 1 mol of 8-arm Lys-PEG interacts with 4 mol of TG-VEGF121 
(Supporting information Figure S3). As we have used excess of TG-VEGF121 (5.4 µg) for the 
immobilization, we assume that the amount of immobilized growth factor cannot be further 
increased. When considering the diameter of TG-VEGF121 (mol wt 32,000 g/mol), based on 
reported VEGF crystal structures52-53, to be in the range of 5 nm the limited growth factor 
coupling is most likely not due to sterical hindrance. There is the possibility that one 
homodimeric TG-VEGF121 molecule interacts with more than two Lys moieties belonging to 
either the same or to a different 8-arm Lys-PEG molecule. However, at this stage we cannot 
provide enough evidence to discuss further scenarios that could explain the observed 
immobilization ratio.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Enzymatic immobilization of vascular endothelial growth factor (TG-VEGF121) by MAPL and OWLS. 
Presence of TG-VEGF121 on MAPL samples was detected with a polyclonal rabbit anti-VEGF antibody and a 
goat anti-rabbit IgG labelled with alexa 555. 60x60 µm squared pattern (green, false colored) was detected in the 
positive sample (a) but not in the control sample (b) in absence of Lys-PEG. Fluorescence intensity (in gray 
scale, original colored images) was measured with “ImageJ’s Plot Profile” function. The scale bar corresponds to 
 
a 
d c 
b 
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100 µm. (c-d) In situ stepwise surface immobilization of different ligands on PLL-g-PEG-TG coated waveguides 
by OWLS (two independent experiments (-) control, (+) positive sample, (*) significantly different (statistical 
analysis performed “dunn test”), n=3). 
 
Stepwise formation of surface immobilized hydrogel-like structures 
Since free and functional substrate domains were observed after individual reaction steps, we 
followed the build-up of a “layer-by-layer” PEG-like hydrogel. Such a system could be used 
to form well-organized surface immobilized growth factor depots. The stepwise FXIIIa-
catalyzed immobilization of Lys-PEG (27.1 ± 3 ng/cm2) followed by TG-PEG (24.2 ± 3.5 
ng/cm2) and subsequently by Lys-PEG (25.1 ± 3.3 ng/cm2) was monitored by OWLS. We 
observed a constant increment of mass for all the steps (Figure 3d). Also for this scenario, we 
believe to reach the maximum amount that can be immobilized. As previously discussed, after 
the first immobilization with Lys-PEG we consider our surface to be saturated with a 
monolayer of Lys-PEG molecules. For the two subsequent immobilization steps (TG-PEG 
and Lys-PEG) our calculations indicate an interaction ratio of 1 to 1, which suggests that a 
monolayer of PEG is being immobilized (Figure 4a) with each step. 
In Figure 4b we contemplate a possible scenario with multifunctional patterned 3D hydrogel-
like structures. We exemplify the immobilization of a first layer of Lys-PEG followed by a 
layer of TG-PEG and a third layer of Lys-PEG. The two first PEG molecules have been 
previously modified to contain one ligand (same or different) per molecule. The presented 
platform, as it is flexible in design, could include PEG molecules variable in number and size 
of arms. Furthermore, PEG molecules could be functionalized with ligands prior to or directly 
upon immobilization to the surface. In combination with other patterning techniques this 
layer-by-layer approach could even be used on hydrogel substrates. Together, we think that 
this stepwise build-up of hydrogel-like structures extends the possibilities of surface confined 
growth factor patterns to more complex 3D arrangement of biomimetic surface immobilized 
hydrogel-like substrates. 
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Figure 4. Illustration of the build-up of hydrogel-like structures. a) Suggested structure of the hydrogel-like 
stepwise immobilization measured by OWLS (Lys-PEG, TG-PEG and Lys-PEG).  b) Conceptual image of a 
possible scenario with multifunctional patterned 3D hydrogel-like structures. 
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Conclusions 
We demonstrated an FXIIIa-catalyzed coupling scheme for site-specific tethering of ligands 
onto a surface that preserves the protein’s bioactivity. Our surface modification method is 
based on the positioning of substrates for FXIIIa on a surface and their usage as initiator 
molecules for the further coupling of ligands. The ligands have been synthesized such that 
they comprised one of the counter reactive substrates for the enzyme. We showed that by 
using the previously described MAPL patterning technology, it is possible to have control 
over the spatial arrangement of the FXIIIa substrates on the surface. By applying a site-
specific FXIIIa-catalyzed enzymatic reaction it is also possible to translate this physical 
arrangement into a bioactive pattern, providing cells not only with adhesive-sites but also with 
morphogenes such as endothelial cell specific mitogen; TG-VEGF121. In addition, we 
provided evidence that this enzymatic approach allows a stepwise formation of more complex 
arrangements and even combinations of bioactive molecules. By recombinant protein 
expression and chemical synthesis a tool box with bioligands engineered to contain substrates 
for FXIIIa can be relatively easy established. These ligands when used together with our site-
specific surface immobilization technique will enable the formation of complex arrangements 
and combinations of bioactive molecules. We therefore believe that this is a versatile and 
powerful 2D platform to study cell-cell and cell-matrix interactions. 
 
 
 
 
 
 
 
 
 20
Acknowledgement  
This work was supported by the Competence Centre for Materials Science and Technology.  
 21
Supporting Information Available:   
PDF file containing four Figures. 1H-NMR analysis of the synthesized PLL-g-PEG-TG 
copolymer (Figure S1). In situ OWLS adsorption of PLL-g-PEG-TG on a titanium-coated 
waveguide and protein resistance of the adsorbed polymer layer (0.3% BSA). The surface was 
also tested for incubation with calcium chloride (25mM) and its resistance to protein 
adsorption was again tested (3% BSA) (Figure S2). A summary of the PLL-g-PEG-TG 
characterization by 1H-NMR and OWLS (molecular weight, grafting ratio, fraction of 
functionalized PEG, polymer adsorbed mass and its protein resistance); theoretical peptide 
densities based on experimental values (theoretical TG peptide surface densities, distance 
between the immobilized TG moieties, molecular weight of ligands used in the study and 
theoretical ligands surface densities) and theoretical immobilization rates on the surface 
(Figure S3). A representative in situ OWLS immobilization graphic; 8-arm Lys-PEG followed 
by TG-VEGF121 (Figure S4). This material is available free of charge via the Internet at 
http://pubs.acs.org. 
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